22 Sep 2025 | 5 Mins Read
Alkem Laboratories launches Pertuza for HER2 breast cancer treatment
Flipitmoney
Alkem Laboratories Ltd launched Pertuza, a locally-developed breast cancer biosimilar, in India. Pertuza is a 420mg/14mL injectable, available for HER2-positive treatment. The drug demonstrated efficacy and safety in phase 3 trials and aims to broaden access to critical cancer care for thousands of women yearly. It further strengthens Alkem's oncology portfolio.